How BIO CEO’s cozy relationship with WuXi soured
As lawmakers take aim at WuXi Apptec, the issue is testing the ability of BIO’s CEO to navigate a domestic policy issue that is tangled up in U.S.-China relations.
As lawmakers take aim at WuXi Apptec, the issue is testing the ability of BIO’s CEO to navigate a domestic policy issue that is tangled up in U.S.-China relations.
Scientists are frustrated that the USDA again failed to include basic information about H5N1 genetic sequences from cows when the data were released this week.
The special sauce of primary care will not be saved until the overwhelming number of quality metrics that primary care providers must complete is winnowed…
After years on the rise, the U.S. maternal mortality rate decreased in 2022, new government data show. But maternal health experts warn there’s no reason…
The DEA is allowing annual and semi-annual production quotas for Schedule II drugs, after it became clear quarterly quotas would worsen shortages.
On Wednesday, UnitedHealth CEO Andrew Witty appeared before Congress to answer for what lawmakers called a “single attack kicked off a cascading series of
The DEA is allowing annual and semi-annual production quotas for Schedule II drugs, after it became clear quarterly quotas would worsen shortages.
The FTC is broadening its campaign to curb alleged patent abuses by the pharma industry, disputing over 300 patent listings across 20 drugs including Ozempic.
Ashish Kamat introduces Jeffrey Holzbeierlein, who discusses the recent updates to the American Urological Association’s (AUA) guidelines for managing non-muscle invasive bladder cancer. Published in…
Despite its devastating impact, colorectal cancer is the only top-five cancer killer without its own research program within the Department of Defense’s Congressionally Directed Medical…
APCCC 2024, metastatic hormone-sensitive prostate cancer (mHSPC), Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography (PSMA-PET), ARCHES trial, enzalutamide, Delta-like ligand 3 (DLL3), LuPSMA.